H.C. Wainwright Believes Antares Pharma (ATRS) Won’t Stop Here


H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Antares Pharma (ATRS) today and set a price target of $4.50. The company’s shares closed yesterday at $3.61, close to its 52-week high of $3.93.

Livnat said:

“Our $4.50 12-month target is based on a sum-of-the-parts after comprising $1.9/share for the other base-business, $0.7/share for other unapproved partnered pipeline, plus $0.3/share NOL’s, less $1.2/share un-allocated OPEX. above components is based on projected individual operating profits, after tax (at 25%), discounted back to 12-months from now at a 10.5% discount rate. We assume a fully-diluted share count of nearly 167M shares.”

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 7.1% and a 57.6% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Jazz Pharmaceuticals, and Agile Therapeutics.

Antares Pharma has an analyst consensus of Strong Buy, with a price target consensus of $5.45, implying a 51.0% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $8 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.93 and a one-year low of $1.58. Currently, Antares Pharma has an average volume of 1.82M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts